Jörgen Jonsson

Ketamine and Esketamine in Clinical Trials: FDA‐Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations

Vekhova, Ksenia A.; Namiot, Eugenia D.; Jonsson, Jörgen; Schiöth, Helgi

Part of Clinical Pharmacology and Therapeutics, p. 374-386, 2025

• DOI for Ketamine and Esketamine in Clinical Trials: FDA‐Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations
• Download full text (pdf) of Ketamine and Esketamine in Clinical Trials: FDA‐Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations

Off-target effects of statins: molecular mechanisms, side effects and the emerging role of kinases

Lagunas-Rangel, Francisco Alejandro; Liepinsh, Edgars; Fredriksson, Robert; Alsehli, Ahmed M. et al.

Part of British Journal of Pharmacology, p. 3799-3818, 2024

• DOI for Off-target effects of statins: molecular mechanisms, side effects and the emerging role of kinases
• Download full text (pdf) of Off-target effects of statins: molecular mechanisms, side effects and the emerging role of kinases

Depression proteomic profiling in adolescents with transcriptome analyses in independent cohorts

Sokolov, Aleksandr V.; Lafta, Muataz; Nordberg, Didi; Jonsson, Jörgen et al.

Part of Frontiers in Psychiatry, 2024

• DOI for Depression proteomic profiling in adolescents with transcriptome analyses in independent cohorts
• Download full text (pdf) of Depression proteomic profiling in adolescents with transcriptome analyses in independent cohorts

Recent developments of topoisomerase inhibitors: Clinical trials, emerging indications, novel molecules and global sales

Bondarev, Andrey D.; Jonsson, Jörgen; Chubarev, Vladimir N.; V. Tarasov, Vadim et al.

Part of Pharmacological Research, 2024

• DOI for Recent developments of topoisomerase inhibitors: Clinical trials, emerging indications, novel molecules and global sales
• Download full text (pdf) of Recent developments of topoisomerase inhibitors: Clinical trials, emerging indications, novel molecules and global sales

Dissecting the Molecular Mechanisms Surrounding Post-COVID-19 Syndrome and Neurological Features

Mohamed, Mohamed S.; Johansson, Anton; Jonsson, Jörgen; Schiöth, Helgi B.

Part of International Journal of Molecular Sciences, 2022

• DOI for Dissecting the Molecular Mechanisms Surrounding Post-COVID-19 Syndrome and Neurological Features
• Download full text (pdf) of Dissecting the Molecular Mechanisms Surrounding Post-COVID-19 Syndrome and Neurological Features

Ketamine and Esketamine in Clinical Trials: FDA‐Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations

Vekhova, Ksenia A.; Namiot, Eugenia D.; Jonsson, Jörgen; Schiöth, Helgi

Part of Clinical Pharmacology and Therapeutics, p. 374-386, 2025

• DOI for Ketamine and Esketamine in Clinical Trials: FDA‐Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations
• Download full text (pdf) of Ketamine and Esketamine in Clinical Trials: FDA‐Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations

Off-target effects of statins: molecular mechanisms, side effects and the emerging role of kinases

Lagunas-Rangel, Francisco Alejandro; Liepinsh, Edgars; Fredriksson, Robert; Alsehli, Ahmed M. et al.

Part of British Journal of Pharmacology, p. 3799-3818, 2024

• DOI for Off-target effects of statins: molecular mechanisms, side effects and the emerging role of kinases
• Download full text (pdf) of Off-target effects of statins: molecular mechanisms, side effects and the emerging role of kinases

Depression proteomic profiling in adolescents with transcriptome analyses in independent cohorts

Sokolov, Aleksandr V.; Lafta, Muataz; Nordberg, Didi; Jonsson, Jörgen et al.

Part of Frontiers in Psychiatry, 2024

• DOI for Depression proteomic profiling in adolescents with transcriptome analyses in independent cohorts
• Download full text (pdf) of Depression proteomic profiling in adolescents with transcriptome analyses in independent cohorts

Recent developments of topoisomerase inhibitors: Clinical trials, emerging indications, novel molecules and global sales

Bondarev, Andrey D.; Jonsson, Jörgen; Chubarev, Vladimir N.; V. Tarasov, Vadim et al.

Part of Pharmacological Research, 2024

• DOI for Recent developments of topoisomerase inhibitors: Clinical trials, emerging indications, novel molecules and global sales
• Download full text (pdf) of Recent developments of topoisomerase inhibitors: Clinical trials, emerging indications, novel molecules and global sales

Recent developments of HDAC inhibitors: Emerging indications and novel molecules

Bondarev, Andrey D; Attwood, Misty M.; Jonsson, Jörgen; Chubarev, Vladimir N et al.

Part of British Journal of Clinical Pharmacology, p. 4577-4597, 2021

• DOI for Recent developments of HDAC inhibitors: Emerging indications and novel molecules
• Download full text (pdf) of Recent developments of HDAC inhibitors: Emerging indications and novel molecules

meQTL and ncRNA functional analyses of 102 GWAS-SNPs associated with depression implicate HACE1 and SHANK2 genes

Ciuculete, Diana-Maria; Voisin, Sarah; Kular, Lara; Jonsson, Jörgen et al.

Part of Clinical Epigenetics, 2020

• DOI for meQTL and ncRNA functional analyses of 102 GWAS-SNPs associated with depression implicate HACE1 and SHANK2 genes
• Download full text (pdf) of meQTL and ncRNA functional analyses of 102 GWAS-SNPs associated with depression implicate HACE1 and SHANK2 genes

A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants

Kanders, Sofia H.; Pisanu, Claudia; Bandstein, Marcus; Jonsson, Jörgen et al.

Part of Drug development research, p. 102-113, 2020

• DOI for A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants
• Download full text (pdf) of A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants

Longitudinal DNA methylation changes at MET may alter HGF/c-MET signalling in adolescents at risk for depression

Ciuculete, Diana Maria; Voisin, Sarah; Kular, Lara; Welihinda, Nipuni et al.

Part of Epigenetics, p. 646-663, 2020

• DOI for Longitudinal DNA methylation changes at MET may alter HGF/c-MET signalling in adolescents at risk for depression
• Download full text (pdf) of Longitudinal DNA methylation changes at MET may alter HGF/c-MET signalling in adolescents at risk for depression

SLC10A4 regulates IgE-mediated mast cell degranulation in vitro and mast cell-mediated reactions in vivo

Pettersson, Hanna; Zarnegar, Behdad; Westin, Annika; Persson, Viktor et al.

Part of Scientific Reports, 2017

• DOI for SLC10A4 regulates IgE-mediated mast cell degranulation in vitro and mast cell-mediated reactions in vivo
• Download full text (pdf) of SLC10A4 regulates IgE-mediated mast cell degranulation in vitro and mast cell-mediated reactions in vivo

Conditional targeting of medium spiny neurons in the striatal matrix

Reinius, Björn; Blunder, Martina; Brett, Frances M.; Eriksson, Anders et al.

Part of Frontiers in Behavioral Neuroscience, 2015

• DOI for Conditional targeting of medium spiny neurons in the striatal matrix
• Download full text (pdf) of Conditional targeting of medium spiny neurons in the striatal matrix

Dissecting the Molecular Mechanisms Surrounding Post-COVID-19 Syndrome and Neurological Features

Mohamed, Mohamed S.; Johansson, Anton; Jonsson, Jörgen; Schiöth, Helgi B.

Part of International Journal of Molecular Sciences, 2022

• DOI for Dissecting the Molecular Mechanisms Surrounding Post-COVID-19 Syndrome and Neurological Features
• Download full text (pdf) of Dissecting the Molecular Mechanisms Surrounding Post-COVID-19 Syndrome and Neurological Features

Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules

Bondarev, Andrey D.; Attwood, Misty M.; Jonsson, Jörgen; Chubarev, Vladimir N. et al.

Part of Frontiers in Pharmacology, 2022

• DOI for Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules
• Download full text (pdf) of Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules

Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales

Dahlén, Amelia; Dashi, Giovanna; Maslov, Ivan; Attwood, Misty M. et al.

Part of Frontiers in Pharmacology, 2022

• DOI for Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
• Download full text (pdf) of Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales

Role of the synergistic interactions of environmental pollutants in the development of cancer

Lagunas-Rangel, Francisco Alejandro; Niemi, Jenni Viivi Linnea; Kudłak, Błażej; Williams, Michael J. et al.

Part of GeoHealth, 2022

• DOI for Role of the synergistic interactions of environmental pollutants in the development of cancer
• Download full text (pdf) of Role of the synergistic interactions of environmental pollutants in the development of cancer

Opportunities and challenges for drug discovery in modulating Adhesion G protein-coupled receptor (GPCR) functions

Bondarev, Andrey D.; Attwood, Misty M.; Jonsson, Jörgen; Chubarev, Vladimir N. et al.

Part of Expert Opinion on Drug Discovery, p. 1291-1307, 2020

• DOI for Opportunities and challenges for drug discovery in modulating Adhesion G protein-coupled receptor (GPCR) functions
• Download full text (pdf) of Opportunities and challenges for drug discovery in modulating Adhesion G protein-coupled receptor (GPCR) functions

Soluble ligands as drug targets

Attwood, Misty M.; Jonsson, Jörgen; Rask-Andersen, Mathias; Schiöth, Helgi B.

Part of Nature reviews. Drug discovery, p. 695-710, 2020

• DOI for Soluble ligands as drug targets